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Estimated glomerular ﬁltration rate
Enzymatic assaysThe National Kidney Disease Education Program group demonstrated that MDRD equation is sensitive to
creatinine measurement error, particularly at higher glomerular ﬁltration rates. Thus, MDRD-based eGFR
above 60 mL/min/1.73 m2 should not be reported numerically. However, little is known about the impact of
analytical error on CKD-EPI-based estimates. This study aimed at assessing the impact of analytical characteris-
tics (bias and imprecision) of 12 enzymatic and 4 compensated Jaffe previously characterized creatinine assays
on MDRD and CKD-EPI eGFR.
In a simulation study, the impact of analytical error was assessed on a hospital population of 24 084 patients.
Ability using each assay to correctly classify patients according to chronic kidney disease (CKD) stages was
evaluated.
For eGFR between 60 and 90 mL/min/1.73 m2, both equations were sensitive to analytical error. Compensated
Jaffe assays displayed high bias in this range and led to poorer sensitivity/speciﬁcity for classiﬁcation according
to CKD stages than enzymatic assays. As compared to MDRD equation, CKD-EPI equation decreases impact of
analytical error in creatinine measurement above 90 mL/min/1.73 m2.
Compensated Jaffe creatinine assays lead to important errors in eGFR and should be avoided. Accurate enzymatic
assays allow estimation of eGFR until 90 mL/min/1.73 m2 with MDRD and 120 mL/min/1.73 m2 with CKD-EPI
equation.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Chronic kidney disease (CKD) is associated with increased risk of
cardiovascular events and overall mortality [1]. Since reliable methods
to measure glomerular ﬁltration rate (GFR) are expensive and difﬁcult,
it is assessed from serum creatinine (Scr) level in clinical practice [2].
However, Scr is also inﬂuenced by gender, age,musclemass and ethnic-
ity. To overcome these potential biases, equations have been developederular ﬁltration rate; Scr, serum
DRD, Modiﬁcation of Diet in
iology Collaboration; NKDEP,
e Dilution Mass Spectrometry;
ney Disease Improving Global
LapeyronieHospital, 191Avenue
nce. Tel.: +33 4 67 33 83 14;
stol).
ghts reserved.to correct Scr for these factors and therefore provide Scr-based estimat-
ed GFR (eGFR).
Modiﬁcation of Diet in Renal Disease (MDRD) [3] and Chronic
Kidney Disease Epidemiology Collaboration (CKD-EPI) [4] equations
are automatically reported by laboratories in many countries. Scr is
the most important variable in all these equations. Moreover, the rela-
tionship between Scr and GFR is exponential. Therefore, errors or
imprecision in Scr measurements could strongly impact eGFR results,
especially in the low Scr levels (highGFR values). As a result, theNation-
al Kidney Disease Education Program (NKDEP) working group recom-
mended in 2006 not to report eGFR higher than 60 mL/min/1.73 m2
numerically [5]. At this time, two types of analytical errors were recog-
nized regarding the measurement of Scr: the analytical imprecision
which is inherent to any biological measurement and the bias which is
the systematic error due to difference in calibration. Regarding this
last point, improvements have been realized in the last years with a
standardization of themeasurementwith the so-called Isotope Dilution
Mass Spectrometry (IDMS) traceability. Even if many manufacturers
90 N. Kuster et al. / Clinica Chimica Acta 428 (2014) 89–95claim their Scr assays are well IDMS traceable, we have in fact relatively
few external and independent proofs of it. Recently, the “Société
Française de Biologie Clinique (SFBC)”working group reported evalua-
tions of currently available IDMS-traceable Scr assays, especially focus-
ing on enzymatic and compensated Jaffe methods [6,7]. If correct
traceability has been found for most enzymatic methods, the results
were less accurate for the compensated Jaffe methods. Also regarding
imprecision, there are reasons to think that enzymatic methods better
perform than Jaffe methodswhich are susceptible to pseudochromogen
interferences [8,9]. Therefore, we think that it still makes sense to study
the analytical error of Scr and the impact on the GFR estimating equa-
tions. In other words, we want to check if, from an analytical point of
view, reporting eGFR results above 60 mL/min/1.73 m2 is suitable in
2013 after improvements in standardization. Also, we analyzed potential
differences between MDRD and CKD-EPI equations, the last one being
now recommended by the Kidney Disease: Improving Global Outcomes
(KDIGO) guidelines [10]. The CKD-EPI equation was still not available
when NKDEP recommended not to report eGFR N60 mL/min/1.73 m2
numerically.2. Material and methods
2.1. Creatinine measurements
The analytical performances of 16 IDMS-traceable analyzers/Scr
assays couples (12 enzymatic: Abbott/Abbott, Beckman Coulter/
Sentinel Diagnostics, FisherKonelab/Kone, Olympus AU 2700/
Diasys, Olympus AU 2700/Olympus, Olympus AU 2700/Randox,
OrthoClinical/OrthoClinical, Roche Cobas 6000/Roche, Roche Modular/
Diasys, Roche Modular/Roche, Siemens Advia/Siemens, Siemens RXL/
Siemens; 4 compensated Jaffe: Olympus AU 2700/Compensated Jaffe,
Roche Cobas 6000/Compensated Jaffe, Roche Modular/Compensated
Jaffe, Siemens Advia/Compensated Jaffe) have been reported by the
SFBC working group and compared to performances' characteristics
proposed by NKDEP on the basis of biological variations of Scr [6,7].
Brieﬂy, Scr level was assigned by gas chromatography IDMS (GC-
IDMS) in the Laboratoire National de Métrologie et d'Essais in ﬁve plas-
ma pools ranging from 35.9 to 174.5 μmol/L. The pools were then
shipped to the laboratories involved in the study. For each assay, Scr
levelwas determined for each pool in 3 laboratories, by 3 repeatedmea-
surements, 3 consecutive days. From these data, biasAssay (mean differ-
ence from IDMS assigned value) and sdAssay (standard deviation of the
measurements) were computed.Table 1
Analytical performances of creatinine assays. Total error for each assay at each creatinine leve
According to the National kidney Disease Education Program, optimum, desirable and minimu






Beckman Coulter/Sentinel Diagnostics 7 11.1
FisherKonelab/Kone 19.5 7.4
Olympus AU 2700/Compensated Jaffe 19.5 11.6
Olympus AU 2700/Diasys 18.5 12.3
Olympus AU 2700/Olympus 8.9 4.1
Olympus AU 2700/Randox 12 8.8
OrthoClinical/OrthoClinical 25.4 7
Roche Cobas 6000/Compensated Jaffe 18.1 12.5
Roche Cobas 6000/Roche 6.9 4.7
Roche Modular/Compensated Jaffe 19.5 11.7
Roche Modular/Diasys 10.9 6.5
Roche Modular/Roche 8.3 3.2
Siemens Advia/Compensated Jaffe 15.3 10.9
Siemens Advia/Siemens 5.7 4.2
Siemens RXL/Siemens 10.2 8.72.2. Study population
Impact of analytical error on eGFR inwas assessed using an unselect-
ed cohort of patients in whom Scr has been measured in the laboratory
of biochemistry, Lapeyronie hospital, CHRU Montpellier, France. The
measurementswere performed between September, 1st andDecember,
31st, 2012 using an enzymatic Roche assay on a Cobas 8000modular an-
alyzer. From an initial database of 87842 measurements, only patients
aged over 18 years old and measured Scr levels lower than 200 μmol/L
were selected in order to match with the SFBC Scr pool levels. For each
patient, only the ﬁrst measurement was kept, leading to a ﬁnal popula-
tion of 24 084 patients.
2.3. Ethical statement
Patients Scr measurements were obtained from the routine labora-
tory database. No permission was required by our institution's Ethics
Committee as the database was fully anonymous and no personal infor-
mation was collected for this study.
2.4. GFR estimation
eGFR was computed using MDRD and CKD-EPI equations. Re-
expressed four-variable MDRD equation for use with IDMS-traceable
assays [11] is expressed as:
eGFR ¼ 30849 Scr‐1:154  Age−0:203 0:742 if Female½ 
 1:212 if Black½ :
CKD-EPI equation [4] can be expressed in a single equation:








 0:993Age 1:018 if Female½  1:159 if Black½ :
With Scr in μmol/L, κ is 62 for females and 80 formales,α is−0.329
for females and−0.411 for males, min indicates the minimum of Scr/κ
or 1 and max indicates the maximum.
2.5. Study design
For each assay, estimations of bias and imprecision for Scr levels
between 20 and 200 μmol/L were extrapolated from the results of the
SFBC study.l was computed through Monte-Carlo simulations with respect to bias and imprecision.

























Ability of creatinine assays to correctly assign chronic kidney disease stages using MDRD and CKD-EPI equations. aSensitivity and speciﬁcity for classiﬁcation of patients considering a 60
and 90 mL/min/1.73 m2 threshold, respectively. bPercentage of patients for whom eGFR error did not exceed 10% of eGFRRef. Sens, sensitivity; Spe, speciﬁcity.
Methode 60 mL/min/1.73 m2 cutoff (%)a 90 mL/min/1.73 m2 cutoff (%)a % patients with error below 10% of eGFRRefb




Sens Spe Sens Spe Sens Spe Sens Spe MDRD CKD-EPI MDRD CKD-EPI
Abbott/Abbott 89.4 100 90.4 100 92.2 99.9 93.7 99.9 100 100 100 100
Beckman Coulter/Sentinel Diagnostics 97.3 97.6 97.3 98 96.7 85.9 97.5 91.1 88.2 90.6 85.8 96.5
FisherKonelab/Kone 99.2 97.5 99.1 98 99.9 81.9 99.9 89.2 97.4 98.9 92.3 99.3
Olympus AU 2700/Compensated Jaffe 88.9 99.8 89.9 99.9 89.2 99 91.4 99.4 93.9 94.8 89.6 96.8
Olympus AU 2700/Diasys 96 97.6 96.6 98.2 96.4 86.5 97.2 91.2 87.9 90.2 84.8 96.2
Olympus AU 2700/Olympus 97.8 98.9 97.6 99.1 98.9 92.1 99 95.7 99.9 99.9 99.8 100
Olympus AU 2700/Randox 98.6 97.4 98.9 97.9 98.3 87.5 98.9 91.8 96.3 96.5 95.7 99.1
OrthoClinical/OrthoClinical 97.2 98.6 97 98.8 99.8 79.2 99.7 88.7 93.7 97.9 76 98.5
Roche Cobas 6000/Compensated Jaffe 99.9 93.7 99.9 95 100 68.6 100 79 66.9 72.5 59.4 89.9
Roche Cobas 6000/Roche 96.4 99.4 97.1 99.5 96.3 97.2 97.1 98.2 99.9 99.9 99.8 100
Roche Modular/Compensated Jaffe 99.9 94.6 100 95.7 100 71.9 100 81.2 76.3 80.8 69.8 92.6
Roche Modular/Diasys 98.5 98.2 98.6 98.6 99.4 88.7 99.4 92.9 99.5 99.6 98.9 99.8
Roche Modular/Roche 99.7 98.8 99.4 99 99.8 92.5 99.9 95.5 100 100 100 100
Siemens Advia/Compensated Jaffe 99.9 94.8 99.8 96 99.9 73.2 99.9 82.7 78.4 81.9 75.1 93.7
Siemens Advia/Siemens 95.5 99.6 96 99.7 97.7 96.9 97.6 98.3 100 100 100 100
Siemens RXL/Siemens 90.3 99.8 90.6 99.8 92 98.2 93.3 99 96.2 96.2 92.7 98.1
91N. Kuster et al. / Clinica Chimica Acta 428 (2014) 89–95In the study population, Scr measurement was carried out on a
Cobas 8000 modular analyzer (c701 module) using the same reagent
as the Roche enzymatic assay assessed by the SFBC study on a Cobas
6000 (c501 module). Although we cannot rule out a difference owing
to platform and/or packaging, we assumed that the bias was similar in
the two systems. Despite this limitation, subtracting the bias of Roche
Cobas 6000/Enzymatic assay to the routine laboratory measurement
provided a reasonably assumed unbiased distribution of Scr levels in
the population, thereafter considered as the reference Scr (ScrRef) level
for this study.
For each patient, Scr levels were simulated according to bias and
imprecision of each assay, yielding to one simulated set of Scr levels by
assay (ScrAssay). Inﬂuence of Scr analytical error on GFR estimation was
then assessed through comparisonof reference Scr-based eGFR (MDRDRef
and CKD-EPIRef) and eGFR computed from ScrAssay (MDRDAssay and CKD-
EPIAssay). Furthermore, ability to correctly classify patients according to






















Fig. 1. Classiﬁcation accuracy according to assay and equation. Sensitivity against speciﬁcity of e
the study population is shown for MDRD and CKD-EPI equations. Abbreviations: Abt/Abt, Ab
Olymp/CJ, Olympus AU2700/Compensated Jaffe; Olmp/Dia, Olympus AU2700/Diasys; Olm
OrthoClinical/OrthoClinical; Cbs/CJ, Roche Cobas 6000/Compensated Jaffe; Cbs/Rch, Roche Coba
Mdl/Rch, Roche Modular/Roche; Adv/CJ, Siemens Advia/Compensated Jaffe; Adv/Smn, Siemens2.6. Statistical analysis
Total error (TE) was computed for each assay and pool was deﬁned
as the 95th percentile of the absolute errors in a random sample of size
10 000 fromanormal distributionwithmean equal to the bias and stan-
dard deviation equal to imprecision of each assay.
Visual inspection of the data from previous SFBC studies [6,7] indi-
cated that bias and imprecision were not linearly related to Scr levels.
Bias and imprecision in the range of 20–200 μmol/L were extrapolated
using locally-weighted polynomial regressions. ScrRef was computed
by subtracting bias observed for the instrument used in our laboratory
to the resultsmeasured in patients. ScrAssay was computed through ran-
dom generation of values following a normal distribution with mean
equal to ScrRef + BiasAssay and standard deviation equal to SdAssay.
Median, 2.5th and 97.5th percentiles of the difference between
eGFRAssay and eGFRRef were assessed using nonparametric quantile














ach assay to detect estimated glomerular ﬁltration rate lower than 90 mL/min/1.73 m2 in
bott/Abbott; BC/Sent, Beckman Coulter/Sentinel Diagnostics; FK/K, FisherKonelab/Kone;
p/Olmp, Olympus AU2700/Olympus; Olmp/Rdx, Olympus AU2700/Randox; Ort/Ort,
s 6000/Roche;Mdl/CJ, RocheModular/Compensated Jaffe;Mdl/Dia, RocheModular/Diasys,
Advia/Siemens; RXL/Smn, Siemens RXL/Siemens.
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assessed through computation of sensitivity and speciﬁcity to predict
eGFR lower than 60 and 90 mL/min/1.73 m2. Accuracy was assessed as
the percentage of estimates that differed by less than 10% from eGFRRef.
All analysis was performed using R 2.15 (Vienna, Austria).
3. Results
Between September, 1st, 2012 and December, 31st, 2012, Scr was
measured in 24084patients aged over 18 years in theDepartment of Bio-
chemistry, Lapeyronie University Hospital, Montpellier, France. Scr mea-
surement was performed using a Roche enzymatic assay on a Cobas
8000 modular analyzer (Hoffman-La Roche, Basel, Switzerland). Mean
age of patients was 55 years old (minimum –maximum, 18–105). Thir-
teen thousand height hundred six (57.3%) patients were aged 18 toFig. 2. Error in estimated glomerular ﬁltration rate according to assay and equation in the study
to analytical error of each assay (eGFRAssay) and reference eGFR (eGFRRef) in the population i
represent MDRD equation. For each equation the 2.5th, 50th and 97.5th percentiles of the diff
E: enzymatic assay, J: Compensated Jaffe assay.60 years, 5810 (24.1%), were aged 61 to 75 years and 4468 (18.6%)
were aged 76 years or older. Gender was male in 12049 patients
(50.0%). According to the routinely reported CKD-EPI based eGFR, 4000
(16.6%) patients had eGFR b 60 mL/min/1.73 m2, 8171 (33.9%) had
eGFR in the range of 60–89 mL/min/1.73 m2 and 11913 (49.5%) had
eGFR greater than 90 mL/min/1.73 m2.
3.1. Performances of currently available creatinine assays
TE for each assay at each Scr pool level is shown in Table 1. Seven of
the 16 assays respect the NKDEP minimum goal of 11.4% [5] at each Scr
level, fromwhich only 3 also respect the desirable threshold of 7.6%. No
assay presented a TE lower than that of the optimal 3.8% goal at all Scr
levels. Maximal error is frequently found at lowest Scr level (pool 1).
At pool 2 level, 3 assays (Beckman Coulter/Sentinel Diagnostics, Rochepopulation. Difference between simulated estimated glomerularﬁltration ratewith respect
s represented against eGFRAssay. Solid lines represent CKD-EPI equation and dashed lines
erences are shown. Letters in bottom left corner of each panel indicate the type of assay.
93N. Kuster et al. / Clinica Chimica Acta 428 (2014) 89–95Modular/Compensated Jaffe, Roche Cobas 6000/Compensated Jaffe)
presented TE greater than those of the minimum goal. Moreover, this
minimum goal was not reached at pool 3 level with Siemens Advia/
Compensated Jaffe assay.
3.2. Enzymatic creatinine assays improve GFR estimation
above 60 mL/min/1.73 m2
As shown in Table 2, in the range of 60–90 mL/min/1.73 m2, GFR
was estimated with an error below 10% for the majority of patients
with enzymatic assays using both equations (mean proportion, 97.5%
and 96.6% with CKD-EPI and MDRD, respectively). Compensated Jaffe
assays did not allow this level of accuracy (mean proportion, 82.5%
and 78.9% with CKD-EPI and MDRD, respectively).
As shown in Fig. 1, compensated Jaffe assays were associated with
the lowest ability to correctly classify patients as having eGFR below
90 mL/min/1.73 m2, because of a lack of sensitivity (compensated
Jaffe/Olympus AU2700) or speciﬁcity (Compensated Jaffe reagents
on Siemens Advia, Roche Modular and Roche Cobas 6000 analyzers). By
contrast, someenzymatic assays displayedboth speciﬁcity and sensitivity
above 95%, with MDRD and CKD-EPI equations (Siemens Advia/Siemens
and Roche Cobas 6000/Roche assays). At 60 mL/min/1.73 m2, a similar




























Assay type : Siemens Advia / Enzym
Fig. 3. Gender-dependant inﬂuence of creatinine error on estimated glomerular ﬁltration rate
Siemens Advia/Enzymatic assay and Siemens Advia/Compensated Jaffe assay, using MDRD an
creatinine levels lower than the gender-dependant CKD-EPI threshold (62 μmol/L in females aAdvia, Roche Modular and Roche Cobas 6000 analyzers yield to a better
speciﬁcity (Table 2).
3.3. CKD-EPI equation reduces impact of analytical error at higher
glomerular ﬁltration rate
Error in eGFR caused by Scr analytical error in the study popula-
tion is shown in Fig. 2. For eGFR below 75 mL/min/1.73 m2, error
was nearly identical with MDRD or CKD-EPI equation. For eGFR equal
to 60 mL/min/1.73 m2, bias, as reﬂected by median difference between
reference eGFR (eGFRRef) and eGFR simulated for each assay (eGFRAssay)
was similar, ranging between −5.2 and 2.0 mL/min/1.73 m2 with
MDRD equation and between −5.3 and 2.1 mL/min/1.73 m2 with
CKD-EPI equation. At higher values, median difference increased with
eGFR when MDRD equation was used but was reduced with CKD-EPI
equation. Maximal bias with CKD-EPI equation is observed for eGFR
close to 75 mL/min/1.73 m2. At 90 mL/min/1.73 m2,median differences
across the assays ranged between −9.0 and 3.7 mL/min/1.73 m2 with
MDRD equation and between −5.9 and 2.1 mL/min/1.73 m2 with
CKD-EPI equation. Impact of imprecision is also reduced with CKD-EPI
equation at higher eGFR, as represented by narrower ranges between
2.5th and 97.5th percentiles. In the range of 90–120 mL/min/1.73 m2,






50 100 150 200
Ref (µmol/L)
atic Siemens Advia / Compensated Jaffe 
. Error in estimated glomerular ﬁltration rate is represented against creatinine level with
d CKD-EPI equations. Using CKD-EPI equation, impact of analytical error is reduced for
nd 80 μmol/L in males, vertical dashed lines).
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assays, 98.9%) whereas MDRD equation was more impacted by analyti-
cal error (mean across enzymatic assays, 93.8%, Table 2).
4. Discussion
Since it has been demonstrated thatmild to moderate CKD is associ-
ated with adverse clinical outcomes [12], the KDIGO working group
recently decided not to combine stage 1–2 CKD [1]. Furthermore, reli-
able estimates of high eGFR are important for drugdosing [13]. A precise
eGFR above 60 mL/min/1.73 m2 is thus valuable, which led to the
development of the CKD-EPI equation. In this study, our goal was
to determinate if the errors due to the Scr measurement were low
enough to allow the laboratories to report numerical eGFR above
60 mL/min/1.73 m2. This study is thus an analytical study with im-
portant clinical implications.
The studies performed by the SFBC working group have highlighted
the improvement of Scr measurement using enzymatic assays but also
pointed out that compensated Jaffe assays do not reach the required
performances [6,7]. Our results extend these observations by focusing
on the consequences on eGFR. Among the 16 assays tested, compensat-
ed Jaffe assays are characterized by poorer performances than their
enzymatic counterparts. The design of the SFBC study, which allowed
different assays to be evaluated on the same analyzer, permits to draw
conclusions about assays independently of the analytic platform. In
this study, Siemens enzymatic reagent with the Siemens Advia analyzer
provided reliable results whereas the compensated Jaffe assay with the
same analyzer yielded deeply biased results. Furthermore, 3 of the 4A B
Fig. 4. Age-dependant effect of systematic creatinine error on estimated glomerular ﬁltration ra
terminationwithMDRD (dashed lines) and CKD-EPI (solid lines) equations for amale aged 30, 6
and CKD-EPI (solid lines) equations in corresponding age groups in the study population using
ment of error caused by creatinine measurement is observed at lower eGFR when age increase
responding to age-dependant eGFR.compensated Jaffe assays tested (compensated Jaffe on Siemens Advia,
Roche Modular and Roche Cobas 6000 analyzers) displayed an impor-
tant negative bias for eGFR in the range of 60–90 mL/min/1.73 m2, as
a result of an overestimation of Scr level. This pattern underscores the
difﬁculty for the manufacturers in correctly realigning theses assays
against the IDMS reference method. The necessity of this realignment
pertains to thewell known interference of ketones, glucose and proteins
with the Jaffe reaction [14]. Almost all the available assays are now sup-
posed to be traceable to IDMS. Nevertheless, our results indicate that all
assays are not equivalent. Surprisingly, little attention has been paid to
this question in a recent KDIGO conferences report [10,15]. Our results
are in line with previous studies concluding that compensated Jaffe
assays should be replaced by enzymatic ones [9,16]. Conversely, a
large proportion of enzymatic assays allow error in eGFR determination
lower than 10% up to 90 mL/min/1.73 m2 using both MDRD and CKD-
EPI equations (Table 2). Enzymatic method allows reporting MDRD
results numerically until 90 mL/min/1.73 m2 which is an improvement
compared to prior recommendation of the NKDEP [5].
Our study also demonstrates that the impact of Scr analytical error
depends on the equation used. CKD-EPI drastically decreases the impact
of Scr measurement error at eGFR above 90 mL/min/1.73 m2. Maximal
susceptibility to analytical error is for Scr close to the threshold be-
tween the two slopes, 62 μmol/L in females and 80 μmol/L in
males, which correspond to eGFR of 120 mL/min/1.73 m2 at age 20
and 75 mL/min/1.73 m2 at age 90 (Fig. 3). This observation comes
from the mathematical model used to develop the equation. The
lower exponent applied to Scr values makes the eGFR far less impacted
by the Scr measurement error (Fig. 4, Panel A) and explains the lowerte Panel A shows the error in eGFR caused by a systematic 4 μmol/L error in creatinine de-
0 and 90 years. Panel B shows themean error in eGFR observedwithMDRD (dashed lines)
Siemens Advia/Compensated Jaffe assay, which presents a bias close to 4 μmol/L. Improve-
s. This is explained by the deﬁnition of the CKD-EPI threshold on the creatinine scale, cor-
95N. Kuster et al. / Clinica Chimica Acta 428 (2014) 89–95error at higher eGFR levels observed in our study (Fig. 4, Panel B). Note-
worthy, because the eGFR corresponding to the CKD-EPI threshold
depends on age, improved robustness is mainly signiﬁcant in patients
aged 60 or older. The use of CKD-EPI equation in our population leads
to a reduction of both bias and imprecision for eGFR higher than
90 mL/min/1.73 m2, therefore allowing estimation of eGFR up to
120 mL/min/1.73 m2.
NKDEP recommendations suggest laboratory to provide GFR estima-
tion along with Scr results [5,17]. Little is known about the impact of
analytical Scr determination on CKD-EPI equation, particularly at higher
GFR. This study allows an estimation of variations of eGFR caused by
analytical errors with a wide panel of assays in a large hospital-based
population. Some limitations must nevertheless be acknowledged.
Mainly, no GFRmeasured by referencemethodswas used and therefore
impact of analytical variations could only be assessed beside eGFR calcu-
lated from IDMS Scr level. Our study showed potential superiority for
the CKD-EPI equation in terms of precision compared to the MDRD
one. However, this superiority is both analytical and theoretical.
In other words, we showed that enzymatic methods allow giving
numerical results with the MDRD equation until 90 mL/min/1.73 m2.
This does not mean that this result is clinically accurate, for example in
comparison with measured GFR and in fact this equation has been
shown to underestimate “true” GFR in high GFR values. In the same
vein, the superiority of the CKD-EPI equation overMDRD is purely analyt-
ical and has not been conﬁrmed by all authors [18]. Moreover, the added
analytical value of the CKD-EPI equation over the MDRD one would be
relevant only in the higher CKD stage (above 90 mL/min/1.73 m2). We
should also keep in mind that CKD-EPI equation, as well as MDRD, has
been derivedmainly from Scr measurement performedwith Jaffe assays,
secondarily realign against enzymatic assays [4,11]. Further studies in
clinical settings may be useful in order to generalize our ﬁndings by con-
sidering together the analytical errors and the errors inherent to each
equation and the errors inherent to the study of various populations.5. Conclusions
Our results highlight that, despite an important effort of standardiza-
tion, choice of Scr assay still greatly impacts accuracy of Scr-based eGFR.
This study also conﬁrms limitations of compensated Jaffe Scr assays.
Results of this study support the use of CKD-EPI equation rather than
MDRD, allowing accurate results at eGFR above 90 mL/min/1.73 m2.
Once again, the better accuracy of the CKD-EPI equation is purely analyt-
ical. One of themost recent recommendations published comes from the
Australasian Creatinine ConsensusWorkingGroupwhich recommended
the use of CKD-EPI equation and a numerical expression at least up to90 mL/min/1.73 m2 [19]. Our study provides a basis for such recommen-
dations and even extends it to eGFR as high as 120 mL/min/1.73 m2, as
long as an accurate enzymatic assay is used.
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